Adam M. Koppel, M.D., Ph.D.

Dr. Adam M. Koppel is a member of the Board of Directors of Beeline Medicines and a Partner at Bain Capital Life Sciences. In addition to Beeline Medicines, he serves on the Boards of Kailera Therapeutics and Cardurion Pharmaceuticals. He has previously served on the Board of Directors for AavantiBio, Aptinyx, Cerevel Therapeutics, Dicerna Pharmaceuticals, Foghorn Therapeutics, PTC Therapeutics, Solid Biosciences, Trevena and ViaCyte. Dr. Koppel was initially at Bain Capital between 2003-2014 before rejoining the firm in 2016 after serving as Executive Vice President of Corporate Development and Chief Strategy Officer at Biogen. Earlier in his career, he was an Associate Principal at McKinsey & Company, advising healthcare organizations. Dr. Koppel received his M.D. and Ph.D. in neuroscience from the Perelman School of Medicine at the University of Pennsylvania and an M.B.A. from Wharton School of the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with A.B. and A.M. degrees in history and science.